Par Pharmaceutical Companies, Inc. and Paddock Holdings, LLC, defeated direct-purchaser plaintiffs’ motion for class certification in the In re AndroGel Antitrust Litigation


White & Case LLP, on behalf of clients Par Pharmaceutical Companies, Inc. and Paddock Holdings, LLC, defeated direct-purchaser plaintiffs’ motion for class certification in the In re AndroGel Antitrust Litigation multi-district litigation proceeding in the US District Court for the Northern District of Georgia.

White & Case partners Eric Grannon (Picture) and Adam Acosta, were counsel on the brief in opposition to class certification, and the court’s order cited the White & Case brief and appendix several times. In re AndroGel are the private cases that parallel the FTC v. Actavis case that resulted in the US Supreme Court’s seminal 2013 decision of the same name, and in which White & Case acted as counsel of record for the same clients before the Supreme Court.

Par Pharmaceutical Companies, Inc. develops, licenses, manufactures, markets, and distributes generic drugs in the United States. The company, led by Paul V. Campanelli operates through two segments, Par Pharmaceutical and Par Specialty Pharmaceuticals.

Involved fees earner: Eric Grannon – White & Case; Adam Acosta – White & Case;

Law Firms: White & Case;

Clients: Par Pharmaceutical Companies, Inc.;

Avatar

Author: Ambrogio Visconti